Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks, shared an article on X:
“Dato-DXd previous BLA (based on TROPION-Lung01) voluntary withdrew and new BLA (based on TROPION-Lung05) submitted for patients with EGFR-m NSCLC!!”
Raffaele Colombo, a leading figure in the pharmaceutical industry is the Associate Director of Medicinal Chemistry at Zymeworks Inc.. His leadership and scientific acumen drive the discovery and optimization of novel drug candidates and advancing the treatment landscape for various diseases.